drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00218 | DB00658 | 1,176 | 965 | [
"DDInter1247",
"DDInter1663"
] | Moxifloxacin | Sevelamer | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel. | Moderate | 1 | [
[
[
1176,
24,
965
]
],
[
[
1176,
21,
28787
],
[
28787,
60,
965
]
],
[
[
1176,
24,
1096
],
[
1096,
63,
965
]
],
[
[
1176,
1,
1539
],
[
1539... | [
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevelamer"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is... | Moxifloxacin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Sevelamer (Compound)
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when... |
DB00108 | DB06589 | 1,066 | 1,250 | [
"DDInter1268",
"DDInter1400"
] | Natalizumab | Pazopanib | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Major | 2 | [
[
[
1066,
25,
1250
]
],
[
[
1066,
25,
1419
],
[
1419,
24,
1250
]
],
[
[
1066,
24,
1270
],
[
1270,
63,
1250
]
],
[
[
1066,
25,
713
],
[
713... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may ... | Natalizumab may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative ... |
DB00635 | DB09280 | 1,573 | 1,604 | [
"DDInter1515",
"DDInter1101"
] | Prednisone | Lumacaftor | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Moderate | 1 | [
[
[
1573,
24,
1604
]
],
[
[
1573,
24,
1171
],
[
1171,
24,
1604
]
],
[
[
1573,
25,
593
],
[
593,
24,
1604
]
],
[
[
1573,
40,
1547
],
[
1547... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
],
[
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Prednisone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a mo... |
DB01224 | DB11110 | 623 | 603 | [
"DDInter1553",
"DDInter1115"
] | Quetiapine | Magnesium citrate | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
623,
24,
603
]
],
[
[
623,
64,
57
],
[
57,
24,
603
]
],
[
[
623,
24,
1616
],
[
1616,
24,
603
]
],
[
[
623,
24,
484
],
[
484,
63,... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Quetiapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Quetiapine may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and His... |
DB00095 | DB00432 | 66 | 1,083 | [
"DDInter623",
"DDInter1868"
] | Efalizumab | Trifluridine | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine] . It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activit... | Moderate | 1 | [
[
[
66,
24,
1083
]
],
[
[
66,
24,
1238
],
[
1238,
1,
1083
]
],
[
[
66,
24,
139
],
[
139,
63,
1083
]
],
[
[
66,
63,
58
],
[
58,
24,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluridine"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
],
[... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin and Pentostatin (Compound) resembles Trifluridine (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that c... |
DB00673 | DB08893 | 723 | 271 | [
"DDInter112",
"DDInter1229"
] | Aprepitant | Mirabegron | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significa... | Minor | 0 | [
[
[
723,
23,
271
]
],
[
[
723,
24,
371
],
[
371,
40,
271
]
],
[
[
723,
6,
8374
],
[
8374,
45,
271
]
],
[
[
723,
21,
28956
],
[
28956,
... | [
[
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
],
[
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Propafenone and Propafenone (Compound) resembles Mirabegron (Compound)
Aprepitant (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mirabegron (Compound)
Aprepitant (Compound) causes Palpitations (Side Effect) and Palp... |
DB00717 | DB09074 | 1,197 | 1,362 | [
"DDInter1312",
"DDInter1327"
] | Norethisterone | Olaparib | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [no... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
1197,
24,
1362
]
],
[
[
1197,
24,
1683
],
[
1683,
24,
1362
]
],
[
[
1197,
64,
353
],
[
353,
24,
1362
]
],
[
[
1197,
1,
1336
],
[
1336,... | [
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
... | Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Norethisterone may lead to a major life threatening interaction when taken with Griseofulvin and Griseofulvi... |
DB00365 | DB00526 | 839 | 1,555 | [
"DDInter842",
"DDInter1355"
] | Grepafloxacin | Oxaliplatin | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Major | 2 | [
[
[
839,
25,
1555
]
],
[
[
839,
62,
141
],
[
141,
24,
1555
]
],
[
[
839,
25,
79
],
[
79,
24,
1555
]
],
[
[
839,
25,
1213
],
[
1213,
... | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Floxuridine"
],
[
"Flox... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Grepafloxacin may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may c... |
DB00321 | DB00757 | 21 | 1,166 | [
"DDInter78",
"DDInter581"
] | Amitriptyline | Dolasetron | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Major | 2 | [
[
[
21,
25,
1166
]
],
[
[
21,
24,
19
],
[
19,
40,
1166
]
],
[
[
21,
24,
85
],
[
85,
1,
1166
]
],
[
[
21,
6,
12523
],
[
12523,
45,
... | [
[
[
"Amitriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyo... | Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine (Compound) resembles Dolasetron (Compound)
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine (Compound) resembles Dolasetron (Compou... |
DB00916 | DB01165 | 112 | 1,539 | [
"DDInter1202",
"DDInter1325"
] | Metronidazole | Ofloxacin | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Minor | 0 | [
[
[
112,
23,
1539
]
],
[
[
112,
62,
1176
],
[
1176,
1,
1539
]
],
[
[
112,
23,
945
],
[
945,
40,
1539
]
],
[
[
112,
23,
739
],
[
739,
... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moxifloxacin"
],
[... | Metronidazole may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Ofloxacin (Compound)
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Ofloxacin (Co... |
DB01169 | DB05294 | 57 | 1,069 | [
"DDInter120",
"DDInter1917"
] | Arsenic trioxide | Vandetanib | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
57,
25,
1069
]
],
[
[
57,
6,
8374
],
[
8374,
45,
1069
]
],
[
[
57,
62,
1247
],
[
1247,
23,
1069
]
],
[
[
57,
24,
659
],
[
659,
6... | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Arsenic trioxide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Arsenic trioxide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vandetanib (Compound)
Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Vandetani... |
DB01432 | DB11581 | 857 | 1,456 | [
"DDInter368",
"DDInter1926"
] | Cholestyramine | Venetoclax | Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water. | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Moderate | 1 | [
[
[
857,
24,
1456
]
],
[
[
857,
63,
126
],
[
126,
24,
1456
]
],
[
[
857,
62,
543
],
[
543,
24,
1456
]
],
[
[
857,
25,
1510
],
[
1510,
... | [
[
[
"Cholestyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Cholestyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
... | Cholestyramine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Cholestyramine may cause a minor interaction that can limit clinical effects when taken with Loperamide and Lope... |
DB00420 | DB01169 | 508 | 57 | [
"DDInter1532",
"DDInter120"
] | Promazine | Arsenic trioxide | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Major | 2 | [
[
[
508,
25,
57
]
],
[
[
508,
6,
8374
],
[
8374,
45,
57
]
],
[
[
508,
23,
112
],
[
112,
23,
57
]
],
[
[
508,
24,
603
],
[
603,
63,
... | [
[
[
"Promazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Promazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ars... | Promazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Arsenic trioxide (Compound)
Promazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Arsenic trioxide
Promaz... |
DB00204 | DB00889 | 228 | 1,133 | [
"DDInter580",
"DDInter840"
] | Dofetilide | Granisetron | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Major | 2 | [
[
[
228,
25,
1133
]
],
[
[
228,
6,
8374
],
[
8374,
45,
1133
]
],
[
[
228,
21,
29282
],
[
29282,
60,
1133
]
],
[
[
228,
23,
112
],
[
112,
... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
]
],
[
[
"Dofetilide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Granis... | Dofetilide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Granisetron (Compound)
Dofetilide (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Granisetron (Compound)
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and... |
DB00405 | DB01591 | 128 | 667 | [
"DDInter517",
"DDInter1696"
] | Dexbrompheniramine | Solifenacin | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
128,
24,
667
]
],
[
[
128,
24,
830
],
[
830,
63,
667
]
],
[
[
128,
24,
104
],
[
104,
24,
667
]
],
[
[
128,
63,
352
],
[
352,
24,... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindami... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00388 | DB11124 | 1,636 | 209 | [
"DDInter1453",
"DDInter1560"
] | Phenylephrine | Racepinephrine | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Racepinephrine is a racemic mixture consisting of d- and l- enantiomers. Epinephrine is a non-selective α- and β-adrenergic receptor agonist. It is a bronchodilator used in the temporary relief of mild symptoms of intermittent asthma including wheezing, tightness of chest and shortness of breath. It is an active ingred... | Moderate | 1 | [
[
[
1636,
24,
209
]
],
[
[
1636,
24,
688
],
[
688,
24,
209
]
],
[
[
1636,
63,
1152
],
[
1152,
24,
209
]
],
[
[
1636,
25,
1053
],
[
1053,
... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Racepinephrine"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]... | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Racepinephrine
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Liothyronin... |
DB00554 | DB00741 | 1,027 | 167 | [
"DDInter1478",
"DDInter885"
] | Piroxicam | Hydrocortisone | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
1027,
24,
167
]
],
[
[
1027,
24,
1220
],
[
1220,
40,
167
]
],
[
[
1027,
24,
870
],
[
870,
1,
167
]
],
[
[
1027,
63,
251
],
[
251,
... | [
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Hydr... |
DB00795 | DB06595 | 50 | 1,491 | [
"DDInter1725",
"DDInter1214"
] | Sulfasalazine | Midostaurin | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
50,
24,
1491
]
],
[
[
50,
63,
176
],
[
176,
24,
1491
]
],
[
[
50,
24,
927
],
[
927,
63,
1491
]
],
[
[
50,
25,
629
],
[
629,
24,
... | [
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
... | Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with En... |
DB00280 | DB09076 | 494 | 1,116 | [
"DDInter575",
"DDInter1899"
] | Disopyramide | Umeclidinium | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Moderate | 1 | [
[
[
494,
24,
1116
]
],
[
[
494,
24,
849
],
[
849,
24,
1116
]
],
[
[
494,
25,
401
],
[
401,
24,
1116
]
],
[
[
494,
63,
352
],
[
352,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Disopyramide may lead to a major life threatening interaction when taken with Promethazine and Promethazine ... |
DB00512 | DB00586 | 91 | 1,512 | [
"DDInter1916",
"DDInter537"
] | Vancomycin | Diclofenac | Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatm... | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Moderate | 1 | [
[
[
91,
24,
1512
]
],
[
[
91,
24,
1263
],
[
1263,
63,
1512
]
],
[
[
91,
6,
10612
],
[
10612,
45,
1512
]
],
[
[
91,
21,
29455
],
[
29455,
... | [
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
],
[
... | Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac and Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac
Vancomycin (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Diclofenac (Compound)
Vancomycin (Compou... |
DB00982 | DB09389 | 1,517 | 517 | [
"DDInter991",
"DDInter1315"
] | Isotretinoin | Norgestrel | Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in... | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Moderate | 1 | [
[
[
1517,
24,
517
]
],
[
[
1517,
24,
129
],
[
129,
24,
517
]
],
[
[
1517,
24,
1017
],
[
1017,
63,
517
]
],
[
[
1517,
25,
1510
],
[
1510,
... | [
[
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
... | Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib an... |
DB00341 | DB00662 | 1,242 | 717 | [
"DDInter343",
"DDInter1873"
] | Cetirizine | Trimethobenzamide | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Moderate | 1 | [
[
[
1242,
24,
717
]
],
[
[
1242,
21,
28762
],
[
28762,
60,
717
]
],
[
[
1242,
24,
1382
],
[
1382,
63,
717
]
],
[
[
1242,
24,
109
],
[
109,... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Cetirizine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is... | Cetirizine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Trimethobenzamide (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Trim... |
DB00250 | DB01394 | 10 | 1,554 | [
"DDInter475",
"DDInter431"
] | Dapsone | Colchicine | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Moderate | 1 | [
[
[
10,
24,
1554
]
],
[
[
10,
6,
3486
],
[
3486,
45,
1554
]
],
[
[
10,
21,
28810
],
[
28810,
60,
1554
]
],
[
[
10,
24,
1017
],
[
1017,
... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colchicine"
]
],
[
[
"Dapsone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Dapsone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Colchicine (Compound)
Dapsone (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Colchicine (Compound)
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Lorl... |
DB09038 | DB14509 | 1,450 | 1,399 | [
"DDInter636",
"DDInter1081"
] | Empagliflozin | Lithium carbonate | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1450,
24,
1399
]
],
[
[
1450,
63,
874
],
[
874,
23,
1399
]
],
[
[
1450,
63,
820
],
[
820,
24,
1399
]
],
[
[
1450,
24,
927
],
[
927,
... | [
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
... | Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Alimemaz... |
DB00224 | DB01166 | 215 | 477 | [
"DDInter917",
"DDInter379"
] | Indinavir | Cilostazol | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Major | 2 | [
[
[
215,
25,
477
]
],
[
[
215,
6,
8374
],
[
8374,
45,
477
]
],
[
[
215,
21,
29340
],
[
29340,
60,
477
]
],
[
[
215,
24,
126
],
[
126,
... | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
]
],
[
[
"Indinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cilostazo... | Indinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Indinavir (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Cilostazol (Compound)
Indinavir may cause a moderate interaction that could exacerbate diseases when tak... |
DB00196 | DB12941 | 600 | 466 | [
"DDInter743",
"DDInter481"
] | Fluconazole | Darolutamide | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Minor | 0 | [
[
[
600,
23,
466
]
],
[
[
600,
35,
1622
],
[
1622,
23,
466
]
],
[
[
600,
24,
1623
],
[
1623,
23,
466
]
],
[
[
600,
25,
351
],
[
351,
... | [
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Fluconazole",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken... | Fluconazole (Compound) resembles Voriconazole (Compound) and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Fluconazole may cause a moderate interaction t... |
DB06372 | DB06643 | 259 | 1,136 | [
"DDInter1594",
"DDInter500"
] | Rilonacept | Denosumab | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
259,
24,
1136
]
],
[
[
259,
63,
1213
],
[
1213,
24,
1136
]
],
[
[
259,
24,
1316
],
[
1316,
63,
1136
]
],
[
[
259,
64,
1377
],
[
1377,
... | [
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
... | Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab and Durvaluma... |
DB06777 | DB08827 | 780 | 990 | [
"DDInter348",
"DDInter1085"
] | Chenodeoxycholic acid | Lomitapide | Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decre... | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
780,
25,
990
]
],
[
[
780,
6,
8374
],
[
8374,
45,
990
]
],
[
[
780,
21,
28701
],
[
28701,
60,
990
]
],
[
[
780,
63,
322
],
[
322,
... | [
[
[
"Chenodeoxycholic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Chenodeoxycholic acid",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Comp... | Chenodeoxycholic acid (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound)
Chenodeoxycholic acid (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Lomitapide (Compound)
Chenodeoxycholic acid may cause a moderate interaction that could exacerbate diseases ... |
DB00563 | DB11601 | 663 | 1,270 | [
"DDInter1174",
"DDInter1889"
] | Methotrexate | Tuberculin purified protein derivative | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
663,
24,
1270
]
],
[
[
663,
24,
350
],
[
350,
24,
1270
]
],
[
[
663,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
663,
63,
1555
],
[
1555,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Methotrexate may lead to a major life threatening interaction when taken with Cl... |
DB00467 | DB11827 | 1,467 | 433 | [
"DDInter644",
"DDInter669"
] | Enoxacin | Ertugliflozin | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
1467,
24,
433
]
],
[
[
1467,
25,
959
],
[
959,
24,
433
]
],
[
[
1467,
64,
251
],
[
251,
24,
433
]
],
[
[
1467,
40,
1176
],
[
1176,
... | [
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Enoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glipizide"
],
[
"Glipizide",
... | Enoxacin may lead to a major life threatening interaction when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Enoxacin may lead to a major life threatening interaction when taken with Betamethasone and Betamethasone may cause a moderate i... |
DB00985 | DB09272 | 1,443 | 412 | [
"DDInter562",
"DDInter632"
] | Dimenhydrinate | Eluxadoline | Dimehydrinate was first described in the literature in 1949, and patented in 1950. Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery. Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyl... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
1443,
24,
412
]
],
[
[
1443,
63,
1594
],
[
1594,
24,
412
]
],
[
[
1443,
24,
830
],
[
830,
24,
412
]
],
[
[
1443,
24,
407
],
[
407,
... | [
[
[
"Dimenhydrinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Dimenhydrinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],... | Dimenhydrinate may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Dimenhydrinate may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine... |
DB01233 | DB11632 | 1,311 | 580 | [
"DDInter1197",
"DDInter1343"
] | Metoclopramide | Opicapone | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine.[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) in... | Moderate | 1 | [
[
[
1311,
24,
580
]
],
[
[
1311,
64,
104
],
[
104,
24,
580
]
],
[
[
1311,
24,
830
],
[
830,
24,
580
]
],
[
[
1311,
63,
1219
],
[
1219,
... | [
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methdilazine"
],
[
"M... | Metoclopramide may lead to a major life threatening interaction when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Pheninda... |
DB01232 | DB06603 | 1,327 | 39 | [
"DDInter1640",
"DDInter1387"
] | Saquinavir | Panobinostat | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1327,
25,
39
]
],
[
[
1327,
62,
112
],
[
112,
23,
39
]
],
[
[
1327,
64,
455
],
[
455,
24,
39
]
],
[
[
1327,
25,
578
],
[
578,
63... | [
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Saquinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Saquinavir may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Saquinavir may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may ca... |
DB00446 | DB06448 | 597 | 171 | [
"DDInter351",
"DDInter1087"
] | Chloramphenicol | Lonafarnib | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Major | 2 | [
[
[
597,
25,
171
]
],
[
[
597,
63,
254
],
[
254,
24,
171
]
],
[
[
597,
24,
112
],
[
112,
24,
171
]
],
[
[
597,
24,
310
],
[
310,
63,... | [
[
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
[
"... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Metronidazo... |
DB08912 | DB11560 | 1,040 | 1,678 | [
"DDInter462",
"DDInter1038"
] | Dabrafenib | Lesinurad | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter assoc... | Moderate | 1 | [
[
[
1040,
24,
1678
]
],
[
[
1040,
62,
168
],
[
168,
23,
1678
]
],
[
[
1040,
24,
466
],
[
466,
63,
1678
]
],
[
[
1040,
63,
1374
],
[
1374,
... | [
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lesinurad"
]
],
[
[
"Dabrafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
... | Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Lesinurad
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutam... |
DB00900 | DB06210 | 45 | 72 | [
"DDInter544",
"DDInter631"
] | Didanosine | Eltrombopag | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Moderate | 1 | [
[
[
45,
24,
72
]
],
[
[
45,
24,
384
],
[
384,
63,
72
]
],
[
[
45,
63,
467
],
[
467,
24,
72
]
],
[
[
45,
24,
14
],
[
14,
24,
72... | [
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
... | Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simv... |
DB01030 | DB12267 | 869 | 1,476 | [
"DDInter1835",
"DDInter233"
] | Topotecan | Brigatinib | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
869,
24,
1476
]
],
[
[
869,
24,
1612
],
[
1612,
23,
1476
]
],
[
[
869,
63,
168
],
[
168,
23,
1476
]
],
[
[
869,
63,
1184
],
[
1184,
... | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezom... |
DB08901 | DB11979 | 1,468 | 1,320 | [
"DDInter1492",
"DDInter625"
] | Ponatinib | Elagolix | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1468,
24,
1320
]
],
[
[
1468,
63,
168
],
[
168,
23,
1320
]
],
[
[
1468,
24,
1427
],
[
1427,
24,
1320
]
],
[
[
1468,
63,
1249
],
[
1249... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxeti... |
DB00358 | DB01232 | 1,010 | 1,327 | [
"DDInter1140",
"DDInter1640"
] | Mefloquine | Saquinavir | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Major | 2 | [
[
[
1010,
25,
1327
]
],
[
[
1010,
24,
833
],
[
833,
1,
1327
]
],
[
[
1010,
25,
915
],
[
915,
40,
1327
]
],
[
[
1010,
6,
8374
],
[
8374,
... | [
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lopinavir"
],
[
"Lopinavir",... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir and Lopinavir (Compound) resembles Saquinavir (Compound)
Mefloquine may lead to a major life threatening interaction when taken with Atazanavir and Atazanavir (Compound) resembles Saquinavir (Compound)
Mefloquine (Compo... |
DB00526 | DB11978 | 1,555 | 124 | [
"DDInter1355",
"DDInter822"
] | Oxaliplatin | Glasdegib | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1555,
24,
124
]
],
[
[
1555,
23,
1247
],
[
1247,
23,
124
]
],
[
[
1555,
24,
112
],
[
112,
23,
124
]
],
[
[
1555,
24,
1079
],
[
1079,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Oxaliplatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Oxaliplatin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazol... |
DB00647 | DB01177 | 675 | 77 | [
"DDInter528",
"DDInter904"
] | Dextropropoxyphene | Idarubicin | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
675,
24,
77
]
],
[
[
675,
6,
6017
],
[
6017,
45,
77
]
],
[
[
675,
7,
11074
],
[
11074,
46,
77
]
],
[
[
675,
7,
5178
],
[
5178,
5... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Dextropropoxyphene",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by ... | Dextropropoxyphene (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Idarubicin (Compound)
Dextropropoxyphene (Compound) upregulates HERC6 (Gene) and HERC6 (Gene) is upregulated by Idarubicin (Compound)
Dextropropoxyphene (Compound) upregulates XBP1 (Gene) and XBP1 (Gene) is downregulated by Idarubicin (Comp... |
DB00738 | DB13928 | 485 | 1,385 | [
"DDInter1420",
"DDInter1660"
] | Pentamidine | Semaglutide | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
485,
24,
1385
]
],
[
[
485,
25,
1154
],
[
1154,
24,
1385
]
],
[
[
485,
24,
1399
],
[
1399,
63,
1385
]
],
[
[
485,
64,
839
],
[
839,
... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasire... | Pentamidine may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium c... |
DB11186 | DB11823 | 1,609 | 858 | [
"DDInter1427",
"DDInter673"
] | Pentoxyverine | Esketamine | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant, and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists. Pentoxyverine acts on sigma-1... | Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide.[L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. Eske... | Moderate | 1 | [
[
[
1609,
24,
858
]
],
[
[
1609,
63,
272
],
[
272,
24,
858
]
],
[
[
1609,
63,
272
],
[
272,
63,
506
],
[
506,
24,
858
]
],
[
[
1609,
... | [
[
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
... | Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Chl... |
DB06168 | DB11627 | 1,531 | 1,367 | [
"DDInter281",
"DDInter860"
] | Canakinumab | Hepatitis B Vaccine (Recombinant) | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
1531,
24,
1367
]
],
[
[
1531,
63,
1083
],
[
1083,
24,
1367
]
],
[
[
1531,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
1531,
24,
1480
],
[
14... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tr... | Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Canakinumab may lead to a major life threatening interaction when taken with Cladrib... |
DB01583 | DB09564 | 624 | 1,296 | [
"DDInter1075",
"DDInter930"
] | Liotrix | Insulin degludec | Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal s... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
624,
24,
1296
]
],
[
[
624,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
624,
24,
761
],
[
761,
24,
1296
]
],
[
[
624,
1,
542
],
[
542,
... | [
[
[
"Liotrix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Liotrix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
... | Liotrix may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Liotrix may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Sax... |
DB00060 | DB01406 | 912 | 984 | [
"DDInter947",
"DDInter472"
] | Interferon beta-1a | Danazol | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Moderate | 1 | [
[
[
912,
24,
984
]
],
[
[
912,
24,
1546
],
[
1546,
1,
984
]
],
[
[
912,
24,
1026
],
[
1026,
40,
984
]
],
[
[
912,
24,
883
],
[
883,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danazol"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestoste... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Danazol (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone and Oxandrolone (Compound) r... |
DB00104 | DB01276 | 966 | 123 | [
"DDInter1323",
"DDInter706"
] | Octreotide | Exenatide | Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
966,
24,
123
]
],
[
[
966,
24,
1252
],
[
1252,
23,
123
]
],
[
[
966,
24,
546
],
[
546,
63,
123
]
],
[
[
966,
63,
1685
],
[
1685,
... | [
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
... | Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate and L... |
DB00195 | DB09340 | 726 | 1,013 | [
"DDInter198",
"DDInter1895"
] | Betaxolol (ophthalmic) | Tyropanoic acid | Betaxolol is a propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydoxy is substituted by a 4-[2-(cyclopropylmethoxy)ethyl]phenyl group and one of the hydrogens attached to the amino group is substituted by isopropyl. It is a selective beta1-receptor blocker and is used in the treatment... | Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac. The molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image ... | Moderate | 1 | [
[
[
726,
24,
1013
]
],
[
[
726,
24,
777
],
[
777,
24,
1013
]
],
[
[
726,
1,
819
],
[
819,
24,
1013
]
],
[
[
726,
24,
777
],
[
777,
6... | [
[
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tyropanoic acid"
]
],
[
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopromide"
],
[
... | Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid
Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Iopromide and Iopromide may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid
Beta... |
DB00220 | DB12941 | 798 | 466 | [
"DDInter1276",
"DDInter481"
] | Nelfinavir | Darolutamide | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Moderate | 1 | [
[
[
798,
24,
466
]
],
[
[
798,
23,
1374
],
[
1374,
23,
466
]
],
[
[
798,
63,
600
],
[
600,
23,
466
]
],
[
[
798,
25,
351
],
[
351,
2... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Nelfinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
],
[
... | Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluco... |
DB00262 | DB00851 | 552 | 611 | [
"DDInter302",
"DDInter463"
] | Carmustine | Dacarbazine | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Moderate | 1 | [
[
[
552,
24,
611
]
],
[
[
552,
5,
11556
],
[
11556,
44,
611
]
],
[
[
552,
6,
7950
],
[
7950,
45,
611
]
],
[
[
552,
54,
19138
],
[
19138,
... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Carmustine",
"{u} (Compound) treats {v} (Disease)",
"melanoma"
],
[
"melanoma",
"{u} (Disease) is treated by {v... | Carmustine (Compound) treats melanoma (Disease) and melanoma (Disease) is treated by Dacarbazine (Compound)
Carmustine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Dacarbazine (Compound)
Carmustine (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic... |
DB04865 | DB09570 | 4 | 1,480 | [
"DDInter1335",
"DDInter1002"
] | Omacetaxine mepesuccinate | Ixazomib | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
4,
24,
1480
]
],
[
[
4,
24,
987
],
[
987,
63,
1480
]
],
[
[
4,
63,
440
],
[
440,
24,
1480
]
],
[
[
4,
24,
1136
],
[
1136,
24,
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Omacetaxine mepesuccinate... |
DB09143 | DB11730 | 313 | 351 | [
"DDInter1701",
"DDInter1588"
] | Sonidegib | Ribociclib | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
313,
25,
351
]
],
[
[
313,
25,
283
],
[
283,
62,
351
]
],
[
[
313,
63,
288
],
[
288,
24,
351
]
],
[
[
313,
64,
1249
],
[
1249,
2... | [
[
[
"Sonidegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Sonidegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may... | Sonidegib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Sonidegib may cause a moderate interaction that could exacerbate diseases when taken with Butalbital and Butalbital may cause a mo... |
DB00559 | DB00907 | 152 | 290 | [
"DDInter223",
"DDInter427"
] | Bosentan | Cocaine (topical) | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Cocaine can cause developmental toxicity and female reproductive toxicity according to an independent committee of scientific and health experts. | Moderate | 1 | [
[
[
152,
24,
290
]
],
[
[
152,
6,
6017
],
[
6017,
45,
290
]
],
[
[
152,
21,
28681
],
[
28681,
60,
290
]
],
[
[
152,
24,
629
],
[
629,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cocaine"
]
],
[
[
"Bosentan",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Cocaine
Bosentan (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Cocaine (Compound)
Bosentan (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Cocaine (Compound)
Bosentan ... |
DB04868 | DB06643 | 478 | 1,136 | [
"DDInter1293",
"DDInter500"
] | Nilotinib | Denosumab | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
478,
24,
1136
]
],
[
[
478,
64,
1213
],
[
1213,
24,
1136
]
],
[
[
478,
74,
1419
],
[
1419,
24,
1136
]
],
[
[
478,
63,
482
],
[
482,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
... | Nilotinib may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Nilotinib (Compound) resembles Imatinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases wh... |
DB05812 | DB15091 | 1,374 | 676 | [
"DDInter8",
"DDInter1901"
] | Abiraterone | Upadacitinib | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Moderate | 1 | [
[
[
1374,
24,
676
]
],
[
[
1374,
24,
283
],
[
283,
24,
676
]
],
[
[
1374,
25,
1593
],
[
1593,
24,
676
]
],
[
[
1374,
24,
1654
],
[
1654,
... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
... | Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Abiraterone may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may ca... |
DB00099 | DB00112 | 440 | 374 | [
"DDInter735",
"DDInter201"
] | Filgrastim | Bevacizumab | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells.[A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its at... | Moderate | 1 | [
[
[
440,
24,
374
]
],
[
[
440,
24,
384
],
[
384,
63,
374
]
],
[
[
440,
24,
770
],
[
770,
64,
374
]
],
[
[
440,
24,
384
],
[
384,
63,... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bevacizumab"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Bevacizumab
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thal... |
DB09118 | DB11691 | 1,580 | 1,499 | [
"DDInter1711",
"DDInter1258"
] | Stiripentol | Naldemedine | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
1580,
24,
1499
]
],
[
[
1580,
63,
723
],
[
723,
24,
1499
]
],
[
[
1580,
64,
1670
],
[
1670,
24,
1499
]
],
[
[
1580,
25,
1406
],
[
1406... | [
[
[
"Stiripentol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Stiripentol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[... | Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Stiripentol may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cau... |
DB00635 | DB00776 | 1,573 | 1,335 | [
"DDInter1515",
"DDInter1360"
] | Prednisone | Oxcarbazepine | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Moderate | 1 | [
[
[
1573,
24,
1335
]
],
[
[
1573,
24,
1605
],
[
1605,
1,
1335
]
],
[
[
1573,
63,
1236
],
[
1236,
1,
1335
]
],
[
[
1573,
23,
307
],
[
307,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
],
[... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Indapamide and Indapamide (Compound) resembles Oxcarbazepine (Compound)
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine (Compound) resembles Oxcarbazepine... |
DB01132 | DB05812 | 1,130 | 1,374 | [
"DDInter1472",
"DDInter8"
] | Pioglitazone | Abiraterone | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
1130,
24,
1374
]
],
[
[
1130,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
1130,
21,
28661
],
[
28661,
60,
1374
]
],
[
[
1130,
63,
798
],
[
... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Pioglitazone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compou... | Pioglitazone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Pioglitazone (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Abiraterone (Compound)
Pioglitazone may cause a moderate interaction that could exacerbate diseases... |
DB00414 | DB06343 | 590 | 1,379 | [
"DDInter16",
"DDInter1766"
] | Acetohexamide | Teprotumumab | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by th... | Moderate | 1 | [
[
[
590,
24,
1379
]
],
[
[
590,
24,
1296
],
[
1296,
63,
1379
]
],
[
[
590,
24,
1254
],
[
1254,
24,
1379
]
],
[
[
590,
63,
1179
],
[
1179,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teprotumumab"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with I... |
DB09048 | DB09098 | 555 | 98 | [
"DDInter1284",
"DDInter1700"
] | Netupitant | Somatrem | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug i... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
555,
24,
98
]
],
[
[
555,
24,
159
],
[
159,
63,
98
]
],
[
[
555,
63,
1573
],
[
1573,
24,
98
]
],
[
[
555,
64,
1478
],
[
1478,
24... | [
[
[
"Netupitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Netupitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Netupitant may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Netupitant may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Pr... |
DB00563 | DB08896 | 663 | 292 | [
"DDInter1174",
"DDInter1576"
] | Methotrexate | Regorafenib | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Moderate | 1 | [
[
[
663,
24,
292
]
],
[
[
663,
63,
79
],
[
79,
1,
292
]
],
[
[
663,
6,
4973
],
[
4973,
45,
292
]
],
[
[
663,
21,
29429
],
[
29429,
6... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Regorafenib (Compound)
Methotrexate (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Regorafenib (Compound)
Methotrexate (Compound) causes Infestation NOS (Side Effect) and... |
DB01284 | DB10675 | 1,042 | 961 | [
"DDInter1782",
"DDInter1065"
] | Tetracosactide | Licorice | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Licorice allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
1042,
24,
961
]
],
[
[
1042,
24,
1231
],
[
1231,
24,
961
]
],
[
[
1042,
63,
1214
],
[
1214,
24,
961
]
],
[
[
1042,
24,
1231
],
[
1231,... | [
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
],
... | Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Min... |
DB06212 | DB09065 | 165 | 760 | [
"DDInter1833",
"DDInter424"
] | Tolvaptan | Cobicistat | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
165,
25,
760
]
],
[
[
165,
63,
1101
],
[
1101,
23,
760
]
],
[
[
165,
63,
1195
],
[
1195,
24,
760
]
],
[
[
165,
24,
868
],
[
868,
... | [
[
[
"Tolvaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",... | Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib m... |
DB00067 | DB11978 | 317 | 124 | [
"DDInter1921",
"DDInter822"
] | Vasopressin | Glasdegib | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
317,
24,
124
]
],
[
[
317,
23,
112
],
[
112,
23,
124
]
],
[
[
317,
24,
79
],
[
79,
24,
124
]
],
[
[
317,
63,
521
],
[
521,
24,
... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sora... |
DB01225 | DB08822 | 500 | 911 | [
"DDInter645",
"DDInter156"
] | Enoxaparin | Azilsartan medoxomil | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in ... | Moderate | 1 | [
[
[
500,
24,
911
]
],
[
[
500,
63,
217
],
[
217,
1,
911
]
],
[
[
500,
21,
29173
],
[
29173,
60,
911
]
],
[
[
500,
64,
1061
],
[
1061,
... | [
[
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olmesartan"
]... | Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Enoxaparin (Compound) causes Oedema peripheral (Side Effect) and Oedema peripheral (Side Effect) is caused by Azilsartan medoxomil (Compound)
Enoxapar... |
DB00861 | DB12130 | 914 | 1,017 | [
"DDInter551",
"DDInter1094"
] | Diflunisal | Lorlatinib | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
914,
24,
1017
]
],
[
[
914,
63,
590
],
[
590,
24,
1017
]
],
[
[
914,
24,
976
],
[
976,
24,
1017
]
],
[
[
914,
25,
1421
],
[
1421,
... | [
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[... | Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and... |
DB06335 | DB08899 | 761 | 129 | [
"DDInter1646",
"DDInter649"
] | Saxagliptin | Enzalutamide | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
761,
24,
129
]
],
[
[
761,
63,
918
],
[
918,
1,
129
]
],
[
[
761,
6,
8374
],
[
8374,
45,
129
]
],
[
[
761,
21,
28703
],
[
28703,
... | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Saxagliptin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Saxagliptin (Compound) causes Pruritus (Side Effect) and... |
DB01176 | DB08883 | 537 | 1,597 | [
"DDInter453",
"DDInter1428"
] | Cyclizine | Perampanel | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning ... | Moderate | 1 | [
[
[
537,
24,
1597
]
],
[
[
537,
63,
100
],
[
100,
24,
1597
]
],
[
[
537,
40,
104
],
[
104,
24,
1597
]
],
[
[
537,
24,
1311
],
[
1311,
... | [
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perampanel"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[... | Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Perampanel
Cyclizine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interactio... |
DB00372 | DB00393 | 999 | 854 | [
"DDInter1793",
"DDInter1295"
] | Thiethylperazine | Nimodipine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Moderate | 1 | [
[
[
999,
24,
854
]
],
[
[
999,
24,
84
],
[
84,
40,
854
]
],
[
[
999,
63,
1428
],
[
1428,
40,
854
]
],
[
[
999,
24,
1419
],
[
1419,
6... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nimodipine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nisoldipine"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Nisoldipine and Nisoldipine (Compound) resembles Nimodipine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Nimodipi... |
DB00497 | DB06791 | 828 | 1,446 | [
"DDInter1366",
"DDInter1021"
] | Oxycodone | Lanreotide | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Moderate | 1 | [
[
[
828,
24,
1446
]
],
[
[
828,
25,
1017
],
[
1017,
63,
1446
]
],
[
[
828,
24,
159
],
[
159,
63,
1446
]
],
[
[
828,
63,
1324
],
[
1324,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",... | Oxycodone may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may ca... |
DB09098 | DB12332 | 98 | 1,619 | [
"DDInter1700",
"DDInter1626"
] | Somatrem | Rucaparib | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural dispo... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
98,
24,
1619
]
],
[
[
98,
63,
222
],
[
222,
23,
1619
]
],
[
[
98,
62,
271
],
[
271,
23,
1619
]
],
[
[
98,
24,
907
],
[
907,
23,
... | [
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Somatrem may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron ma... |
DB00489 | DB09132 | 17 | 492 | [
"DDInter1704",
"DDInter797"
] | Sotalol | Gadoteric acid | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Gadoteric acid, commonly used in the salt form gadoterate meglumine, is a macrocyclic, ionic gadolinium-based contrast agent (GBCA). It is composed of the organic acid DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) used for its chelating properties, and gadolinium (Gd3+). Gadoterate meglumine has one o... | Moderate | 1 | [
[
[
17,
24,
492
]
],
[
[
17,
1,
88
],
[
88,
24,
492
]
],
[
[
17,
21,
28644
],
[
28644,
60,
1081
],
[
1081,
24,
492
]
],
[
[
17,
1,
... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadoteric acid"
]
],
[
[
"Sotalol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate ... | Sotalol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Sotalol (Compound) causes Syncope (Side Effect) and Syncope (Side Effect) is caused by Nicardipine (Compound) and Nicardipine may cause a moderate interaction ... |
DB09065 | DB11689 | 760 | 321 | [
"DDInter424",
"DDInter1659"
] | Cobicistat | Selumetinib | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Major | 2 | [
[
[
760,
25,
321
]
],
[
[
760,
25,
982
],
[
982,
63,
321
]
],
[
[
760,
64,
392
],
[
392,
24,
321
]
],
[
[
760,
25,
498
],
[
498,
24,... | [
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Selumetinib"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} ... | Cobicistat may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Cobicistat may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate inter... |
DB00401 | DB09098 | 84 | 98 | [
"DDInter1298",
"DDInter1700"
] | Nisoldipine | Somatrem | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
84,
24,
98
]
],
[
[
84,
1,
336
],
[
336,
24,
98
]
],
[
[
84,
24,
159
],
[
159,
63,
98
]
],
[
[
84,
24,
1573
],
[
1573,
24,
... | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Nisoldipine",
"{u} (Compound) resembles {v} (Compound)",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a moderat... | Nisoldipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that... |
DB01591 | DB09073 | 667 | 951 | [
"DDInter1696",
"DDInter1379"
] | Solifenacin | Palbociclib | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
667,
24,
951
]
],
[
[
667,
24,
1476
],
[
1476,
63,
951
]
],
[
[
667,
25,
351
],
[
351,
63,
951
]
],
[
[
667,
63,
600
],
[
600,
2... | [
[
[
"Solifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Solifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[... | Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Solifenacin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cau... |
DB00344 | DB11186 | 1,302 | 1,609 | [
"DDInter1543",
"DDInter1427"
] | Protriptyline | Pentoxyverine | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
1302,
24,
1609
]
],
[
[
1302,
24,
104
],
[
104,
24,
1609
]
],
[
[
1302,
40,
1236
],
[
1236,
24,
1609
]
],
[
[
1302,
63,
701
],
[
701,
... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
... | Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Protriptyline (Compound) resembles Carbamazepine (Compound) and Carbamazepine may cause a moderate int... |
DB00060 | DB00722 | 912 | 743 | [
"DDInter947",
"DDInter1079"
] | Interferon beta-1a | Lisinopril | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Moderate | 1 | [
[
[
912,
24,
743
]
],
[
[
912,
24,
610
],
[
610,
40,
743
]
],
[
[
912,
24,
1638
],
[
1638,
1,
743
]
],
[
[
912,
24,
384
],
[
384,
63... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Lisinopril (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Lisi... |
DB00584 | DB00712 | 610 | 1,274 | [
"DDInter638",
"DDInter763"
] | Enalapril | Flurbiprofen | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypert... | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Moderate | 1 | [
[
[
610,
24,
1274
]
],
[
[
610,
6,
10612
],
[
10612,
45,
1274
]
],
[
[
610,
21,
28769
],
[
28769,
60,
1274
]
],
[
[
610,
24,
1613
],
[
161... | [
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Enalapril",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compound)... | Enalapril (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Flurbiprofen (Compound)
Enalapril (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Flurbiprofen (Compound)
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Pe... |
DB00622 | DB11348 | 1,081 | 1,065 | [
"DDInter1287",
"DDInter279"
] | Nicardipine | Calcium Phosphate | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
1081,
24,
1065
]
],
[
[
1081,
40,
336
],
[
336,
24,
1065
]
],
[
[
1081,
40,
336
],
[
336,
40,
854
],
[
854,
24,
1065
]
],
[
[
1081,
... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Nicardipine",
"{u} (Compound) resembles {v} (Compound)",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause ... | Nicardipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Nicardipine (Compound) resembles Nifedipine (Compound) and Nifedipine (Compound) resembles Nimodipine (Compound) and Nimodipine may cause a moderate int... |
DB00372 | DB01238 | 999 | 673 | [
"DDInter1793",
"DDInter118"
] | Thiethylperazine | Aripiprazole | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Moderate | 1 | [
[
[
999,
24,
673
]
],
[
[
999,
24,
827
],
[
827,
40,
673
]
],
[
[
999,
24,
1630
],
[
1630,
1,
673
]
],
[
[
999,
24,
1374
],
[
1374,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Aripiprazole (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Aripip... |
DB00451 | DB01083 | 542 | 1,142 | [
"DDInter1064",
"DDInter1348"
] | Levothyroxine | Orlistat | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical inter... | Moderate | 1 | [
[
[
542,
24,
1142
]
],
[
[
542,
6,
8374
],
[
8374,
45,
1142
]
],
[
[
542,
21,
28900
],
[
28900,
60,
1142
]
],
[
[
542,
24,
5
],
[
5,
... | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Levothyroxine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Levothyroxine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Orlistat (Compound)
Levothyroxine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Orlistat (Compound)
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Lira... |
DB06704 | DB08918 | 247 | 41 | [
"DDInter952",
"DDInter1059"
] | Iobenguane (I-131) | Levomilnacipran | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Major | 2 | [
[
[
247,
37,
41
]
],
[
[
247,
76,
901
],
[
901,
40,
41
]
],
[
[
247,
6,
7390
],
[
7390,
45,
41
]
],
[
[
247,
21,
28921
],
[
28921,
6... | [
[
[
"Iobenguane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Iobenguane",
"{u} may cause a moderate interaction that ... | Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Iobenguane may lead to a major life threatening interaction when taken with Levomilnacipran
Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Iobenguane... |
DB01088 | DB03404 | 714 | 765 | [
"DDInter908",
"DDInter855"
] | Iloprost | Hemin | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand. | Moderate | 1 | [
[
[
714,
24,
765
]
],
[
[
714,
24,
840
],
[
840,
63,
765
]
],
[
[
714,
63,
291
],
[
291,
24,
765
]
],
[
[
714,
64,
1172
],
[
1172,
2... | [
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
],
[
"Vorap... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar and Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Argatroban and Argatroban may ca... |
DB00041 | DB08868 | 1,648 | 1,011 | [
"DDInter38",
"DDInter737"
] | Aldesleukin | Fingolimod | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1648,
25,
1011
]
],
[
[
1648,
24,
242
],
[
242,
63,
1011
]
],
[
[
1648,
24,
1136
],
[
1136,
24,
1011
]
],
[
[
1648,
25,
876
],
[
876,
... | [
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesiv... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denos... |
DB01589 | DB11186 | 481 | 1,609 | [
"DDInter1552",
"DDInter1427"
] | Quazepam | Pentoxyverine | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
481,
24,
1609
]
],
[
[
481,
24,
649
],
[
649,
24,
1609
]
],
[
[
481,
63,
506
],
[
506,
24,
1609
]
],
[
[
481,
40,
523
],
[
523,
... | [
[
[
"Quazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Quazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
... | Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and D... |
DB09331 | DB11003 | 745 | 748 | [
"DDInter478",
"DDInter100"
] | Daratumumab | Anthrax vaccine | Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the trea... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
745,
24,
748
]
],
[
[
745,
25,
676
],
[
676,
63,
748
]
],
[
[
745,
63,
1683
],
[
1683,
24,
748
]
],
[
[
745,
64,
1057
],
[
1057,
... | [
[
[
"Daratumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Daratumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"U... | Daratumumab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Daratumumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinum... |
DB00031 | DB06404 | 20 | 1,514 | [
"DDInter1764",
"DDInter869"
] | Tenecteplase | Human C1-esterase inhibitor | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | C1 Esterase Inhibitor (Human) is composed of purified endogenous complement component-1 esterase inhibitor (hC1INH) isolated from human plasma. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways.[L16586, L16606] This drug is indicated for prophylaxis and... | Moderate | 1 | [
[
[
20,
24,
1514
]
],
[
[
20,
25,
4
],
[
4,
63,
1581
],
[
1581,
24,
1514
]
],
[
[
20,
25,
126
],
[
126,
24,
1581
],
[
1581,
24,
15... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human C1-esterase inhibitor"
]
],
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesucci... | Tenecteplase may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Testolactone and Testolactone may cause a moderate interaction that could exacerbate diseases when taken w... |
DB01174 | DB08881 | 697 | 868 | [
"DDInter1442",
"DDInter1925"
] | Phenobarbital | Vemurafenib | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
697,
25,
868
]
],
[
[
697,
6,
8374
],
[
8374,
45,
868
]
],
[
[
697,
21,
29106
],
[
29106,
60,
868
]
],
[
[
697,
62,
608
],
[
608,
... | [
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Phenobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"... | Phenobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Phenobarbital (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Vemurafenib (Compound)
Phenobarbital may cause a minor interaction that can limit clinical effects when taken with Lidocaine and ... |
DB00261 | DB00404 | 702 | 523 | [
"DDInter93",
"DDInter54"
] | Anagrelide | Alprazolam | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down ... | Moderate | 1 | [
[
[
702,
24,
523
]
],
[
[
702,
24,
1119
],
[
1119,
1,
523
]
],
[
[
702,
7,
13042
],
[
13042,
46,
523
]
],
[
[
702,
18,
6797
],
[
6797,
... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alprazolam"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlordiazepoxide"
],
... | Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Chlordiazepoxide and Chlordiazepoxide (Compound) resembles Alprazolam (Compound)
Anagrelide (Compound) upregulates HIST1H2BK (Gene) and HIST1H2BK (Gene) is upregulated by Alprazolam (Compound)
Anagrelide (Compound) downregulates ... |
DB00317 | DB14568 | 883 | 982 | [
"DDInter810",
"DDInter1000"
] | Gefitinib | Ivosidenib | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
883,
24,
982
]
],
[
[
883,
63,
1101
],
[
1101,
23,
982
]
],
[
[
883,
24,
627
],
[
627,
24,
982
]
],
[
[
883,
40,
1195
],
[
1195,
... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir and Bictegrav... |
DB01263 | DB06335 | 859 | 761 | [
"DDInter1494",
"DDInter1646"
] | Posaconazole | Saxagliptin | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
859,
24,
761
]
],
[
[
859,
6,
8374
],
[
8374,
45,
761
]
],
[
[
859,
21,
28966
],
[
28966,
60,
761
]
],
[
[
859,
25,
1491
],
[
1491,
... | [
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Posaconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Posaconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saxagliptin (Compound)
Posaconazole (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Saxagliptin (Compound)
Posaconazole may lead to a major life threatening intera... |
DB00661 | DB09143 | 122 | 313 | [
"DDInter1928",
"DDInter1701"
] | Verapamil | Sonidegib | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Major | 2 | [
[
[
122,
25,
313
]
],
[
[
122,
24,
478
],
[
478,
24,
313
]
],
[
[
122,
25,
1478
],
[
1478,
24,
313
]
],
[
[
122,
25,
484
],
[
484,
6... | [
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
... | Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Verapamil may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moder... |
DB00176 | DB00213 | 529 | 837 | [
"DDInter770",
"DDInter1388"
] | Fluvoxamine | Pantoprazole | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Moderate | 1 | [
[
[
529,
24,
837
]
],
[
[
529,
24,
1215
],
[
1215,
40,
837
]
],
[
[
529,
6,
6017
],
[
6017,
45,
837
]
],
[
[
529,
21,
29455
],
[
29455,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) resembles Pantoprazole (Compound)
Fluvoxamine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Pantoprazole (Compound)
Fluvoxamine (Compound) causes Agranulocytosis (Side Effe... |
DB00465 | DB01124 | 886 | 1,411 | [
"DDInter1010",
"DDInter1828"
] | Ketorolac | Tolbutamide | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
886,
24,
1411
]
],
[
[
886,
24,
959
],
[
959,
40,
1411
]
],
[
[
886,
63,
245
],
[
245,
40,
1411
]
],
[
[
886,
21,
28746
],
[
28746,
... | [
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
... |
DB00708 | DB00792 | 1,454 | 832 | [
"DDInter1718",
"DDInter1878"
] | Sufentanil | Tripelennamine | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to w... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
1454,
24,
832
]
],
[
[
1454,
24,
100
],
[
100,
63,
832
]
],
[
[
1454,
24,
649
],
[
649,
1,
832
]
],
[
[
1454,
63,
1594
],
[
1594,
... | [
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],... | Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Clofeda... |
DB01024 | DB11601 | 1,096 | 1,270 | [
"DDInter1252",
"DDInter1889"
] | Mycophenolic acid | Tuberculin purified protein derivative | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
1096,
24,
1270
]
],
[
[
1096,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
1096,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
1096,
63,
599
],
[
599... | [
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken wit... | Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Mycophenolic acid may lead to a major life threatening interaction when tak... |
DB00745 | DB12130 | 307 | 1,017 | [
"DDInter1236",
"DDInter1094"
] | Modafinil | Lorlatinib | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Major | 2 | [
[
[
307,
25,
1017
]
],
[
[
307,
62,
608
],
[
608,
23,
1017
]
],
[
[
307,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
307,
62,
175
],
[
175,
... | [
[
[
"Modafinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
... | Modafinil may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may... |
DB00247 | DB00618 | 1,131 | 1,572 | [
"DDInter1194",
"DDInter498"
] | Methysergide | Demeclocycline | An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize sero... | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | Moderate | 1 | [
[
[
1131,
24,
1572
]
],
[
[
1131,
24,
1620
],
[
1620,
1,
1572
]
],
[
[
1131,
24,
1669
],
[
1669,
40,
1572
]
],
[
[
1131,
25,
384
],
[
384,... | [
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
]
],
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
]... | Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline (Compound) resembles Demeclocycline (Compound)
Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline (Compound) resembles Demecloc... |
DB00501 | DB09104 | 752 | 286 | [
"DDInter380",
"DDInter1118"
] | Cimetidine | Magnesium hydroxide | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Minor | 0 | [
[
[
752,
23,
286
]
],
[
[
752,
24,
481
],
[
481,
23,
286
]
],
[
[
752,
23,
1482
],
[
1482,
23,
286
]
],
[
[
752,
63,
1119
],
[
1119,
... | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
],
... | Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Digitoxin and Digito... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.